{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T06:22:28Z","timestamp":1774678948099,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["MH078437"],"award-info":[{"award-number":["MH078437"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["schres-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.schres.2014.09.038","type":"journal-article","created":{"date-parts":[[2014,10,18]],"date-time":"2014-10-18T10:53:07Z","timestamp":1413629587000},"page":"73-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial"],"prefix":"10.1016","volume":"160","author":[{"given":"Timothy L.","family":"Ramsey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark D.","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2014.09.038_bb0005","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/mp.2010.14","article-title":"Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs","volume":"16","author":"Adkins","year":"2011","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2014.09.038_bb0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-244X-5-3","article-title":"Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia","volume":"5","author":"Ascher-Svanum","year":"2005","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.schres.2014.09.038_bb0015","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1176\/ajp.2006.163.7.1276","article-title":"Association of initial antipsychotic response to clozapine and long-term weight gain","volume":"163","author":"Bai","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2014.09.038_bb0020","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/bioinformatics\/bth457","article-title":"Haploview: analysis and visualization of LD and haplotype maps","volume":"21","author":"Barrett","year":"2005","journal-title":"Bioinformatics"},{"key":"10.1016\/j.schres.2014.09.038_bb0025","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3102\/10769986025001060","article-title":"On the adaptive control of the false discovery rate in multiple testing with independent statistics","volume":"25","author":"Benjamini","year":"2000","journal-title":"J. Educ. Behav. Stat."},{"key":"10.1016\/j.schres.2014.09.038_bb0030","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00213-005-0062-z","article-title":"Increased salivary cortisol after waking in depression","volume":"182","author":"Bhagwagar","year":"2005","journal-title":"Psychopharmacology (Berl)."},{"key":"10.1016\/j.schres.2014.09.038_bb0035","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2217\/pgs.13.247","article-title":"Genetic variation in the GCG and in the GLP1R genes and antipsychotic-induced weight gain","volume":"15","author":"Brandl","year":"2014","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.schres.2014.09.038_bb0040","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.peptides.2008.04.007","article-title":"Glucagon-like peptide 1 (7\u201336) amide (GLP-1) and exendin-4 stimulate serotonin release in rat hypothalamus","volume":"29","author":"Brunetti","year":"2008","journal-title":"Peptides"},{"key":"10.1016\/j.schres.2014.09.038_bb0045","series-title":"Statistical Power Analysis for the Behavioral Sciences Lawrence Erlbaum Associates","author":"Chohen","year":"1988"},{"key":"10.1016\/j.schres.2014.09.038_bb0050","first-page":"225","article-title":"Second-generation antipsychotic use in schizophrenia and associated weight gain: a critical review and meta-analysis of behavioral and pharmacologic treatments","volume":"24","author":"Das","year":"2012","journal-title":"Ann. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2014.09.038_bb0055","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.physbeh.2013.03.008","article-title":"Antipsychotic-like effect of GLP-1 agonist liraglutide but not DPP-IV inhibitor sitagliptin in mouse model for psychosis","volume":"114\u2013115","author":"Dixit","year":"2013","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.schres.2014.09.038_bb0060","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1741-7015-10-92","article-title":"Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits","volume":"10","author":"Ebdrup","year":"2012","journal-title":"BMC Med."},{"key":"10.1016\/j.schres.2014.09.038_bb0065","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.physbeh.2012.03.014","article-title":"Exendin-4 decreases amphetamine-induced locomotor activity","volume":"106","author":"Erreger","year":"2012","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.schres.2014.09.038_bb0070","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.physbeh.2013.04.003","article-title":"Role of central glucagon-like peptide-1 in stress regulation","volume":"122","author":"Ghosal","year":"2013","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.schres.2014.09.038_bb0075","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1192\/bjp.bp.108.054775","article-title":"Serotonin transporter genotype, morning cortisol and subsequent depression in adolescents","volume":"195","author":"Goodyer","year":"2009","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2014.09.038_bb0080","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/mp.2012.141","article-title":"GLP-1 analog attenuates cocaine reward","volume":"18","author":"Graham","year":"2013","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2014.09.038_bb0085","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.physbeh.2012.02.017","article-title":"Neuronal and intracellular signaling pathways mediating GLP-1 energy balance and glycemic effects","volume":"106","author":"Hayes","year":"2012","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.schres.2014.09.038_bb0090","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.schres.2011.01.022","article-title":"The association between weight change and symptom reduction in the CATIE schizophrenia trial","volume":"128","author":"Hermes","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2014.09.038_bb0095","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1042\/BST20140016","article-title":"Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases","volume":"42","author":"Holscher","year":"2014","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.schres.2014.09.038_bb0100","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1176\/appi.ajp.2013.12101344","article-title":"Sustained weight loss after treatment with a glucagon-like peptide-1 receptor agonist in an obese patient with schizophrenia and type 2 diabetes","volume":"170","author":"Ishoy","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2014.09.038_bb0105","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1124\/mol.111.072884","article-title":"Polymorphism and ligand dependent changes in human glucagon-like peptide-1 receptor (GLP-1R) function: allosteric rescue of loss of function mutation","volume":"80","author":"Koole","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.schres.2014.09.038_bb0110","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/sj.mp.4002136","article-title":"How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials","volume":"14","author":"Leucht","year":"2009","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2014.09.038_bb0115","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.schres.2014.09.038_bb0120","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.2217\/pgs.12.105","article-title":"Targeted pharmacogenetic analysis of antipsychotic response in the CATIE study","volume":"13","author":"Liu","year":"2012","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.schres.2014.09.038_bb0125","article-title":"Sulfotransferase 4A1 haplotype 1 (SULT4A1-1) is associated with decreased hospitalization events in antipsychotic-treated patients with schizophrenia","volume":"14","author":"Liu","year":"2012","journal-title":"Prim. Care Companion CNS Disord."},{"key":"10.1016\/j.schres.2014.09.038_bb0130","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.schres.2008.05.011","article-title":"The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance","volume":"103","author":"Lykkegaard","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2014.09.038_bb0135","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/npp.2010.193","article-title":"Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia","volume":"36","author":"McClay","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2014.09.038_bb0140","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/mp.2009.89","article-title":"Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics","volume":"16","author":"McClay","year":"2011","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2014.09.038_bb0145","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/ejhg.2008.264","article-title":"Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis","volume":"17","author":"Need","year":"2009","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.schres.2014.09.038_bb0150","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.schres.2013.07.008","article-title":"Genotypic variation in the SV2C gene impacts response to atypical antipsychotics the CATIE study","volume":"149","author":"Ramsey","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2014.09.038_bb0155","doi-asserted-by":"crossref","first-page":"E751","DOI":"10.1152\/ajpendo.00367.2013","article-title":"Hindbrain GLP-1 receptor-mediated suppression of food intake requires a PI3K-dependent decrease in phosphorylation of membrane-bound Akt","volume":"305","author":"Rupprecht","year":"2013","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.schres.2014.09.038_bb0160","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.2337\/dc10-0200","article-title":"Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects: a pilot study","volume":"33","author":"Sathananthan","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.schres.2014.09.038_bb0165","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11154-014-9289-5","article-title":"Effects of GLP-1 on appetite and weight","volume":"15","author":"Shah","year":"2014","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.schres.2014.09.038_bb0170","article-title":"GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats","author":"Sharma","year":"2014","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.schres.2014.09.038_bb0175","article-title":"Dipeptidyl-peptidase IV (DPP-IV) inhibitor delays tolerance to anxiolytic effect of ethanol and withdrawal-induced anxiety in rats","author":"Sharma","year":"2014","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.schres.2014.09.038_bb0180","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.pnpbp.2010.05.007","article-title":"Glucagon-like peptide-1 receptor gene polymorphism (Leu260Phe) is associated with morning cortisol in preschoolers","volume":"34","author":"Sheikh","year":"2010","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2014.09.038_bb0190","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/oxfordjournals.schbul.a006986","article-title":"The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development","volume":"29","author":"Stroup","year":"2003","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2014.09.038_bb0185","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1176\/ajp.2007.164.3.415","article-title":"Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study","volume":"164","author":"Stroup","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2014.09.038_bb0195","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.schres.2008.09.009","article-title":"A systematic method for estimating individual responses to treatment with antipsychotics in CATIE","volume":"107","author":"van den Oord","year":"2009","journal-title":"Schizophr. Res."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996414005301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996414005301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T12:20:30Z","timestamp":1538137230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996414005301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":39,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0920996414005301"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2014.09.038","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2014.09.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}